Anti-heparin/PF4 complexes by ELISA in patients with disseminated intravascular coagulation
- PMID: 20224256
- DOI: 10.1159/000296281
Anti-heparin/PF4 complexes by ELISA in patients with disseminated intravascular coagulation
Abstract
Heparin-induced thrombocytopenia (HIT) is known to complicate disseminated intravascular coagulation (DIC), but rarely to be complicated by DIC. We measured the titers of anti-PF4/hepatin complex antibodies by ELISA (HIT-Elisa) and examined 4 parameters of coagulation and fibrinolysis [D-dimer, thrombin/antithrombin complex (TAT), plasmin/alpha2-plasmin inhibitor complex (PIC), and antithrombin levels] in 80 patients with DIC diagnosed by a DIC scoring system. Fourteen patients were HIT-Elisa-positive, 11 of whom received heparin. In 3 of these 11 patients, platelet counts were < or =10 x 10(9)/l and/or reduced by more than 50% for 5-10 days after the heparin (2 patients treated with renal replacement therapy for chronic uremia and postoperative renal failure, and 1 with DIC from a solid tumor). The 3 patients had an optical density reading of >1.0 and a high level of IgG for HIT antibodies, and were thus considered to have DIC complicated with HIT (DIC-HIT). The other 8 patients had optical density readings of 0.4-1.0, and it was unclear whether their thrombocytopenia was caused by HIT alone or by sustained DIC. There were no significant differences in platelet counts and the 4 parameters of coagulation and fibrinolysis between the patients with DIC-HIT and DIC patients with a weakly positive result (0.4-1.0). No differences were observed in platelet counts, or levels of D-dimer and antithrombin between HIT-Elisa-positive and -negative DIC patients. However, the HIT-Elisa-negative patients showed significantly higher levels of TAT and PIC, presumably reflecting DIC-related hypercoagulability. In conclusion, DIC patients treated with heparin occasionally showed HIT antibody seroconversion and developed HIT. HIT-Elisa could assist in the diagnosis of HIT.
Copyright 2010 S. Karger AG, Basel.
Similar articles
-
[Coagulation and fibrinolysis parameters in disseminated intravascular coagulation (DIC)].Rinsho Byori. 1991 Mar;39(3):309-14. Rinsho Byori. 1991. PMID: 1828842 Japanese.
-
Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems.Thromb Haemost. 2004 Feb;91(2):276-82. doi: 10.1160/TH03-07-0454. Thromb Haemost. 2004. PMID: 14961154
-
Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. The Mie DIC Study Group.Pol J Pharmacol. 1996 Mar-Apr;48(2):225-8. Pol J Pharmacol. 1996. PMID: 9112656
-
[Progress in diagnosis of disseminated intravascular coagulation (DIC)--diagnostic criteria of DIC].Nihon Rinsho. 1993 Jan;51(1):43-9. Nihon Rinsho. 1993. PMID: 8433527 Review. Japanese.
-
[A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].Rinsho Byori. 2004 Apr;52(4):355-61. Rinsho Byori. 2004. PMID: 15164605 Review. Japanese.
Cited by
-
Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection.Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620977702. doi: 10.1177/1076029620977702. Clin Appl Thromb Hemost. 2021. PMID: 33539214 Free PMC article. Review.
-
Novel biomarkers for early prediction of sepsis-induced disseminated intravascular coagulation in a mouse cecal ligation and puncture model.J Inflamm (Lond). 2013 Mar 5;10(1):7. doi: 10.1186/1476-9255-10-7. J Inflamm (Lond). 2013. PMID: 23497204 Free PMC article.
-
Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated?Vaccines (Basel). 2022 Feb 16;10(2):308. doi: 10.3390/vaccines10020308. Vaccines (Basel). 2022. PMID: 35214765 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous